Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

Our biosimilar mAbs [monoclonal antibodies] are ... libraries that are among the best in the industry, and proprietary in silico structure-optimization algorithms. Now it is developing technology ...

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...